Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.
Value Health. 2023 Jul;26(7):974-983. doi: 10.1016/j.jval.2023.02.003. Epub 2023 Feb 15.
To determine the effect of socioeconomic status on efficacy and cost thresholds at which theoretical diabetes prevention policies become cost-effective.
We designed a life table model using real-world data that captured diabetes incidence and all-cause mortality in people with and without diabetes by socioeconomic disadvantage. The model used data from the Australian diabetes registry for people with diabetes and the Australian Institute of Health and Welfare for the general population. We simulated theoretical diabetes prevention policies and estimated the threshold at which they would be cost-effective and cost saving, overall, and by socioeconomic disadvantage, from the public healthcare perspective.
From 2020 to 2029, 653 980 people were projected to develop type 2 diabetes, 101 583 in the least disadvantaged quintile and 166 744 in the most. Theoretical diabetes prevention policies that reduce diabetes incidence by 10% and 25% would be cost-effective in the total population at a maximum per person cost of Australian dollar (AU$) 74 (95% uncertainty interval: 53-99) and AU$187 (133-249) and cost saving at AU$26 (20-33) and AU$65 (50-84). Theoretical diabetes prevention policies remained cost-effective at a higher cost in the most versus least disadvantaged quintile (eg, a policy that reduces type 2 diabetes incidence by 25% would be cost-effective at AU$238 [169-319] per person in the most disadvantaged quintile vs AU$144 [103-192] in the least).
Policies targeted at more disadvantaged populations will likely be cost-effective at higher costs and lower efficacy compared to untargeted policies. Future health economic models should incorporate measures of socioeconomic disadvantage to improve targeting of interventions.
确定社会经济地位对理论糖尿病预防政策的效果和成本阈值的影响,使其具有成本效益。
我们使用真实世界的数据设计了一个生命表模型,该模型通过社会经济劣势捕捉了有和没有糖尿病的人群中的糖尿病发病率和全因死亡率。该模型使用了澳大利亚糖尿病登记处的数据和澳大利亚卫生福利研究所的数据。我们模拟了理论上的糖尿病预防政策,并从公共医疗保健的角度估计了它们在总体上以及在社会经济劣势方面具有成本效益和成本节约的阈值。
从 2020 年到 2029 年,预计将有 653980 人患上 2 型糖尿病,其中最不处于劣势的五分位数为 101583 人,最处于劣势的五分位数为 166744 人。在总人口中,将糖尿病发病率降低 10%和 25%的理论上的糖尿病预防政策,在每人最高成本为澳元(AUD)74 (95%置信区间:53-99)和 AUD187(133-249)时具有成本效益,在每人成本为 AUD26(20-33)和 AUD65(50-84)时具有成本节约。在最劣势五分位数与最不劣势五分位数相比,更高成本的理论上的糖尿病预防政策仍然具有成本效益(例如,将 2 型糖尿病发病率降低 25%的政策在最劣势五分位数中的每人成本为 AUD238[169-319],而在最不劣势五分位数中的每人成本为 AUD144[103-192])。
针对更处于劣势的人群的政策,与无针对性政策相比,在更高的成本和更低的效果下,可能具有成本效益。未来的健康经济模型应纳入社会经济劣势的衡量标准,以提高干预措施的针对性。